Aethlon Medical, Inc. announced on June 9, 2025, that an abstract detailing new preclinical data on its Hemopurifier has been accepted for a poster presentation. The presentation will occur at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes, scheduled for August 10-13, 2025.
The poster presentation will review the Hemopurifier's affinity resin's ability to bind extracellular vesicles (EVs) in Long COVID samples. This research, conducted in collaboration with the University of California San Francisco Medical Center Long COVID clinic, investigates whether EVs from Long COVID patients express surface mannose sugar that binds to the Hemopurifier's proprietary GNA lectin.
Long COVID affects an estimated 44 to 48 million people in the United States alone, with a projected economic burden of $2 billion for those with symptoms lasting a year, and currently has no approved treatments. These findings build on prior clinical evidence and support further investigation of the Hemopurifier in this significant unmet medical need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.